Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Characterization and quantitation of antiestrogen binding sites in estrogen receptor-positive and -negative human breast cancer cell lines.

× No keyword cloud information.

21 in total

1. Microsomal epoxide hydrolase expression in the endometrial uterine corpus is regulated by progesterone during the menstrual cycle.

Authors: Simone L Popp; Ina S Abele; Miriam B Buck; Matthias B Stope; Leen J Blok; Payman Hanifi-Moghaddam; Curt W Burger; Peter Fritz; Cornelius Knabbe
Journal: J Mol Histol Date: 2010-04-13 Impact factor: 2.611

2. Microsomal binding sites for antioestrogens in rat liver. Properties and detergent solubilization.

Authors: C K Watts; R L Sutherland
Journal: Biochem J Date: 1986-06-15 Impact factor: 3.857

3. Comparative effect of embryonic mouse fibroblasts (Balb/c-3T3) on the proliferation of hormone-dependent (T-47D) and hormone-independent (MDA-MB-231) human breast cancer cell lines.

Authors: G Chetrite; L Delalonde; J R Pasqualini
Journal: Breast Cancer Res Treat Date: 1993 Impact factor: 4.872

4. Tamoxifen binding sites in human mammary cancers.

Authors: N Fujino; M Kimura; K Sakamoto; N Shigaki; J Yamashita; M Akagi
Journal: Jpn J Surg Date: 1986-09

5. Antiestrogen binding sites in microsomal fractions of malignant and nonmalignant human breast tissues.

Authors: R R Mehta; T K DasGupta
Journal: Breast Cancer Res Treat Date: 1987 Impact factor: 4.872

6. Interaction of unsaturated fatty acids with anti-oestrogen-binding sites.

Authors: P L Hwang
Journal: Biochem J Date: 1987-04-15 Impact factor: 3.857

7. Unsaturated fatty acids as endogenous inhibitors of tamoxifen binding to anti-oestrogen-binding sites.

Authors: P L Hwang
Journal: Biochem J Date: 1986-08-01 Impact factor: 3.857

8. Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites.

Authors: G Scambia; F O Ranelletti; P Benedetti Panici; M Piantelli; G Bonanno; R De Vincenzo; G Ferrandina; L Pierelli; A Capelli; S Mancuso
Journal: Cancer Chemother Pharmacol Date: 1991 Impact factor: 3.333

9. Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer.

Authors: S R Johnston; B P Haynes; N P Sacks; J A McKinna; L J Griggs; M Jarman; M Baum; I E Smith; M Dowsett
Journal: Breast Cancer Res Treat Date: 1993-12 Impact factor: 4.872

10. Overcoming tamoxifen resistance in oestrogen receptor-positive breast cancer using the novel thiosemicarbazone anti-cancer agent, DpC.

Authors: Sundus N Maqbool; Syer C Lim; Kyung Chan Park; Rumeza Hanif; Des R Richardson; Patric J Jansson; Zaklina Kovacevic
Journal: Br J Pharmacol Date: 2020-02-12 Impact factor: 8.739